Nasdaq · Healthcare
CollPlant Biotechnologies Ltd (CLGN)
As-reported financials and recent SEC filings for CollPlant Biotechnologies Ltd, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.4M
Net income
$-11.5M
Net margin
—
Diluted EPS
$-0.94
ROE
-188.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.4M | $515,000 | $11.0M | $299,000 | $15.6M |
| Gross profit | $1.5M | $-1.1M | $9.0M | $-101,000 | $13.6M |
| Operating income | $-11.5M | $-17.3M | $-7.5M | $-17.1M | $65,000 |
| Net income | $-11.5M | $-16.6M | $-7.0M | $-16.9M | $237,000 |
| Diluted EPS | $-0.94 | $-1.45 | $-0.62 | $-1.53 | $0.02 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
6-K2026-07-01
View on EDGAR →6-K2026-05-29
View on EDGAR →32026-04-27
View on EDGAR →EFFECT2026-04-21
View on EDGAR →424B32026-04-21
View on EDGAR →CORRESP2026-04-17
View on EDGAR →F-1/A2026-04-15
View on EDGAR →6-K2026-04-13
View on EDGAR →Largest Healthcare peers
Go deeper on CLGN
Search CollPlant Biotechnologies Ltd’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.